Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 3/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.49 |
| ▸ | AKR1C3 | P42330 | 3/20 | 0.49 |
| ▸ | AKR1C2 | P52895 | 3/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | CDC42 | P60953 | 1/20 | 0.49 |
| ▸ | RAC1 | P63000 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.49 |
| ▸ | CES2 | O00748 | 1/20 | 0.49 |
| ▸ | CES1 | P23141 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.47 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5888900 | 1.00 | PTGS1 (0.53) | PTGS1L3MBTL1SMN1; SMN2POLBPTGS2 | |
| SCHEMBL27606784 | 0.86 | PTGS1 (0.56) | PTGS1L3MBTL1POLBPTGS2AKR1C3 | |
| SCHEMBL10921392 | 0.85 | L3MBTL1 (0.55) | L3MBTL1SMN1; SMN2POLBAKR1C3AKR1C2 | |
| SCHEMBL361183 | 0.84 | PTGS1 (0.73) | PTGS1L3MBTL1SMN1; SMN2PTGS2AKR1C3 | |
| SCHEMBL31635557 | 0.84 | PTGS1 (0.73) | PTGS1L3MBTL1SMN1; SMN2PTGS2AKR1C3 | |
| SCHEMBL10629616 | 0.84 | PTGS1 (0.73) | PTGS1L3MBTL1SMN1; SMN2PTGS2AKR1C3 | |
| SCHEMBL15641441 | 0.84 | PTGS1 (0.73) | PTGS1L3MBTL1SMN1; SMN2PTGS2AKR1C3 | |
| SCHEMBL16800683 | 0.84 | PTGS1 (0.58) | PTGS1L3MBTL1POLBPTGS2AKR1C3 | |
| SCHEMBL3812948 | 0.83 | PTGS1 (0.77) | PTGS1L3MBTL1AKR1C3MEN1KMT2A | |
| SCHEMBL10980506 | 0.83 | PTGS1 (0.47) | PTGS1SMN1; SMN2PTGS2SLC22A6MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8288488-B2 | Process for producing solid catalyst component for olefin polymerization | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-10-16 | — | — | US | disclosed |
| US-20110269929-A1 | PROCESS FOR PRODUCING SOLID CATALYST COMPONENT FOR OLEFIN POLYMERIZATION | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-11-03 | — | — | US | disclosed |
| US-7435729-B2 | Compounds and methods for modulation of estrogen receptors | SIGNAL PHARMACEUTICALS, LLC (US) | 2008-10-14 | — | — | US | disclosed |
| US-7279489-B2 | Compounds and methods for modulation of estrogen receptors | SIGNAL PHARMACEUTICALS, LLC (US) | 2007-10-09 | — | — | US | disclosed |
| US-20050004360-A1 | Compounds and methods for modulation of estrogen receptors | SIGNAL PHARMACEUTICALS, INC. | 2005-01-06 | — | — | US | disclosed |
| US-20040082575-A1 | Compounds and methods for modulation of estrogen receptors | SIGNAL PHARMACEUTICALS, INC. | 2004-04-29 | — | — | US | disclosed |
| US-6686351-B2 | PARTIALLY HYDROGENATED FUSED INDENE, NAPHTHALENE, ISOINDOLE, ISOQUINOLINE, BENZOAZEPINE AND BENZOCYCLOHEPTENE DERIVATIVES SUBSTITUTED BY A HYDROXY GROUP OR DERIVATIVE AND AN ARYL OR N-HETEROARYL GROUP | SIGNAL PHARMACEUTICALS, INC. | 2004-02-03 | — | — | US | disclosed |
| US-6593322-B1 | Methods are disclosed for modulating ER- beta in cell and/or tissues expressing the same, including cells and/ or tissue that preferentially ER- beta . Methods for treating estrogen-related conditions are also disclosed, including | SIGNAL PHARMACEUTICALS, INC. | 2003-07-15 | — | — | US | disclosed |
| EP-1322617-A1 | COMPOUNDS AND METHODS FOR MODULATION OF ESTROGEN RECEPTORS | SIGNAL PHARMACEUTICALS, INC. (US) | 2003-07-02 | — | — | EP | disclosed |
| US-20030087901-A1 | Compounds and methods for modulation of estrogen receptors | SIGNAL PHARMACEUTICALS, INC. | 2003-05-08 | — | — | US | disclosed |
| US-6436923-B1 | ESTROGEN ANTAGONISTS AND/OR AGONISTS FOR TREATING ESTROGEN-RELATED CONDITIONS | SIGNAL PHARMACEUTICALS, INC. | 2002-08-20 | — | — | US | disclosed |
| WO-2002024653-A1 | COMPOUNDS AND METHODS FOR MODULATION OF ESTROGEN RECEPTORS | SIGNAL PHARMACEUTICALS, INC. (US) | 2002-03-28 | — | — | WO | disclosed |
| EP-1163225-A1 | COMPOUNDS AND METHODS FOR MODULATION OF ESTROGEN RECEPTORS | SIGNAL PHARMACEUTICALS, INC. (US) | 2001-12-19 | — | — | EP | disclosed |
| WO-2000055137-A1 | COMPOUNDS AND METHODS FOR MODULATION OF ESTROGEN RECEPTORS | SIGNAL PHARMACEUTICALS, INC. (US) | 2000-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004360-A1 | Compounds and methods for modulation of estrogen receptors | ESRRB, ESR2, ESRRA | PTGS1 1669/4885L3MBTL1 2470/4885SMN1; SMN2 3836/4885 |
| US-20030087901-A1 | Compounds and methods for modulation of estrogen receptors | ESRRB, ESRRA, ESR2 | PTGS1 1711/4885L3MBTL1 2099/4885SMN1; SMN2 3647/4885 |
| US-20040082575-A1 | Compounds and methods for modulation of estrogen receptors | ESRRB, ESRRA, ESR2 | PTGS1 1363/4885L3MBTL1 2001/4885SMN1; SMN2 3204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.